Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lipoproteins – e.g. – egg yolk proteins – cylomicrons – etc.
Reexamination Certificate
2005-02-01
2008-09-23
Lukton, David (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lipoproteins, e.g., egg yolk proteins, cylomicrons, etc.
C530S350000, C514S002600
Reexamination Certificate
active
07427662
ABSTRACT:
Apolipoprotein A-I-rich Lhigh-density Lipoprotein 2 (HDL2) and Apolipoprotein A-I (ApoA-I) was discovered to inhibit angiogenesis in an in vitro human angiogenesis model, the human placental vein angiogenesis model. Apolipoprotein A-I was able to destroy a pre-existing angiogenic response as well as prevent the development of new vessels. Application of Apolipoprotein A-I will be effective in inhibiting tumor growth dependent on angiogenesis, and in decreasing existing blood vessels formed by tumors. It will also be effective in treating non-cancerous diseases which symptoms include an increase in angiogenesis, e.g., psoriasis, retinopathy of prematurity, neovascular glaucoma, diabetic retinopathy, obesity, and psoriasis.
REFERENCES:
patent: 5059528 (1991-10-01), Bollen et al.
patent: 6258596 (2001-07-01), Benoit et al.
patent: 6743428 (2004-06-01), Chang et al.
Schulter V. (Arteriosclerosis, Thrombosis, and Vascular Biology 21 (3) 433-8, 2001).
Fruchart, J.C. et al., “Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance,” Clin. Chem., vol. 38, pp. 793-797 (1992).
Asztalos, B.F. et al., “Normolipidemic subjects with low HDL cholesterol levels have altered HDL subpopulations,” Arterioscler. Thromb. Vasc. Biol., vol. 17, pp. 1885-1893 (1997).
Bicknell, R., “Vascular targeting and the inhibition of angiogenesis,” Annals of Oncology, vol. 5, pp. 45-50 (1994).
Creamer, D. et al., “Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis,”Br. J. Dermatol., vol. 137, pp. 851-855 (1997).
Eerola, A.K. et al., “Tumour infiltrating lymphocytes in relation to tumour angiogenesis, apoptosis,” Lung Cancer, vol. 26, pp. 73-83 (1999).
Gasparini, G., “The rationale and future potential of angiogenesis inhibitors in neoplasia,” Drugs, vol. 58, pp. 17-38 (1999).
Levy, R.I. et al., “The structure, function and metabolism of high-density lipoproteins: A status report,” Circulation, vol. 62, pp. IV4-IV8 (1980).
Maniotis, A.J. et al., “Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry,” Am. J. Pathol., vol. 155, pp. 739-752 (1999).
Rosen, L., “Antiangiogenic strategies and agents in clinical trials,” Oncologist, vol. 5, supplement 1, pp. 20-27 (2000).
Rupnick, M.A. Rupnick, M.A. et al., “Adipose tissue mass can be regulated through the vasculature,” PNAS, vol. 99, pp. 10730-10735 (2002).
Silverman, D.I. et al., “High-density lipoprotein subfractions,” Am. J. Med., vol. 94, pp. 636-645 (1993).
Watson, J.C. et al., “Breast cancer increases initiation of angiogenesis without accelerating neovessel growth rate,” Surgery, vol. 122, pp. 509-514 (1997).
Wenger, F.A. et al., “Tumor size and lymph-node status in pancreatic carcinoma—is there a correlation to the preoperative function?,” Langenbecks Archives of Surgery, vol. 384, pp. 473-478 (1999).
Alaupovic, P, “Significance of Apolipoproteins for Structure, Function, and Classification of Plasma Lipoproteins,” Methods in Enzymology, vol. 263, pp. 32-60 (1996).
Cho, K-H et al., “Role of individual amino acids of apolipoprotein A-I in the activation of lecithin:cholesterol acyltransferase and in HDL rearrangements,” Journal of Lipid Research, vol. 42, pp. 379-389 (2001).
Fazio, S. et al., “Apolipoprotein AI as therapy for atherosclerosis: Does the future of preventive cardiology include weekly injections of the HDL protein?”, Molecular Interventions, vol. 3, pp. 436-440 (2003).
Franceschini, G. et al., High density lipoprotein-3 heterogeneity in subjects with the Apo A-1Milano variant, Journal of Biological Chemistry, vol. 257, pp. 9926-9930 (1982).
Frank, P.G. et al., “Apolipoprotein A-I: structure-function relationships,” Journal of Lipid Research, vol. 41, pp. 853-872 (2001).
Patsch, W. et al., “Apolipoproteins: Pathophysiology and Clinical Implications,” Methods in Enzymology, vol. 263, pp. 3-32 (1996).
Roma, P. et al., “In vivo metabolism of a mutant form of apolipoprotein A-1, apo A-1Milano , associated with familial hypoalphalipoprotenemia,” Journal of Clinical Investigation, vol. 91, pp. 1445-1452 (1993).
Von Eckardstein et al., “Interaction of reconstituted high density lipoprotein discs containing human apolipoprotein A-I (ApoA-I) variants with murine adipocytes and macrophages,” Journal of Biological Chemistry, vol. 268, pp. 2616-2622, (1993).
Ye, S.Q. et al., “Influence of genetic polymorphisms on responsiveness to dietary fat and cholesterol,” American Journal of Clinical Nutrition, vol. 72, pp. 1275S-1284S (2000.
Hornick Conrad A.
Woltering Eugene A.
Baord of Supervisors of Louisiana State University And Agricultu
Davis Bonnie J.
Lukton David
Runnels John H.
LandOfFree
Inhibition of angiogenesis and destruction of angiogenic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of angiogenesis and destruction of angiogenic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of angiogenesis and destruction of angiogenic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3969648